Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure
Latest Information Update: 02 Apr 2025
At a glance
- Drugs Canagliflozin (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms CHIEF-HF
- Sponsors Janssen Research & Development
Most Recent Events
- 01 Jun 2023 Trial design assessing the operational structure and novel strategies employed in a completely DCT by summarizing the recruitment, enrollment, engagement, retention, and follow-up processes used in the execution of the trial at 18 centers published in the Journal of Cardiac Failure
- 01 Apr 2022 Results published in the Nature Medicine
- 07 Dec 2021 Status changed from active, no longer recruiting to completed.